Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

TRIAD · Tolerance Restoration In Autoimmune Diseases by selective manipulation of the CD28 costimulatory pathway

FP7Status: CLOSED1 January 201231 December 2014EU funding €2,959,590

The TRIAD, Tolerance Restoration In Autoimmune Disease, consortium provides an innovative strategy to autoimmune diseases (AID) therapy, based on antibody approach with a well established mechanism of action. The main objective is the evaluation of a selective antagonist of CD28 to prevent, treat and/or cure some AIDs in preclinical models including rheumatoid arthritis, multiple sclerosis, type 1 diabetes, psoriasis, uveitis and arteriosclerosis.The concept is based on rather than suppressing the immune system as a whole, suppressing only the parts of the immune system responsible for the autoimmune attack, while sparing and enhancing regulatory T cells. Costimulation through the CD28/B7/CTLA-4 molecular triad controls the balance effector/regulatory functions after initial antigen exposure. An antagonist anti-CD28 represents a novel drug candidate allowing very specific immunosuppression compatible with regulatory T cells function, immune regulation and therefore tolerance induction/restoration.The TRIAD project will start with the study of the efficacy of a new selective antagonist of CD28 in non-human primate models and the exploration of the potential efficacy of surrogate CD28 antagonist in rodent models. Then will be performed an evaluation of potential immunological toxicity of the antagonist in humanized SCID mice and non-human primate, to exclude agonist activity in vivo. Previously identified mechanisms of action (i.e. costimulation blockade and induction of Tregs) in the context of AID will be confirmed in experimental models. Formulation and preclinical toxicological studies will be run before initiating PhaseI/II trial in patients.TRIAD capitalises on the strong experience available in Brazil and Europe in the field of immunology. It comprises 6 academic institutions and 1 SME being the coordinator of the 3-year project. International cooperation with project is ensured by the integration of a leading Brazilian research centre in the consortium.""

Consortium · 7 organisations

coordinator

EFFIMUNE SAS

FR · €1,310,263

participant

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €418,895

participant

STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

NL · €444,571

participant

THE GLASGOW CALEDONIAN UNIVERSITY

UK · €178,752

participant

SOCIEDADE BENEFICENTE ISRAELITA BRASILEIRA HOSPITAL ALBERT EINSTEIN

BR · €140,293

participant

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

UK · €303,838

participant

CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES

FR · €162,979

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.